On July 29, Maiwei Biotech announced that it had reached a licensing agreement with Saudi Arabian biopharmaceutical company SVAXInc. for 9MW0813. According to the agreement, the two sides will carry out in-depth cooperation on the registration, production and commercialization of products in the Arab Gulf countries.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.